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Abstract: Increased visceral adiposity may influence the development of prostate cancer (PCa) ag-
gressive tumors and cancer mortality. White adipose tissue (WAT), usually referred to as periprostatic
adipose tissue (PPAT), surrounds the prostatic gland and has emerged as a potential mediator of
the tumor microenvironment. Exercise training (ET) induces several adaptations in both skeletal
muscle and WAT. Some of these effects are mediated by ET-induced synthesis and secretion of
several proteins, known as myo- and adipokines. Together, myokines and adipokines may act in
an endocrine-like manner to favor communication between skeletal muscle and WAT, as they may
work together to improve whole-body metabolic health. This crosstalk may constitute a potential
mechanism by which ET exerts its beneficial role in the prevention and treatment of PCa-related
disorders; however, this has not yet been explored. Therefore, we reviewed the current evidence
on the effects of skeletal muscle–WAT–tumor crosstalk in PCa, and the potential mediators of this
process to provide a better understanding of underlying ET-related mechanisms in cancer.
Keywords: physical activity; cancer; tumor microenvironment; visceral adiposity; periprostatic fat;
skeletal muscle
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1. Introduction
Prostate cancer (PCa) has risen to be the second most frequently diagnosed cancer for
males, representing 7.1% of all new cancer cases and 3.8% of all cancer deaths [1].
Existing data on the association between obesity and PCa incidence are inconsistent.
However, some epidemiological evidence has demonstrated an association between obesity,
specifically increased visceral adiposity, and PCa aggressiveness, poor treatment outcomes,
and cancer mortality [2,3]. Considering that male subjects likely accumulate adiposity
centrally, this question is of utmost importance for PCa patients [4].
White adipose tissue (WAT) is an organ closely associated with the etiology and/or
pathophysiology of obesity. It produces a remarkable level of plasticity by increasing or de-
creasing the adipocyte cell size and number or inducing a brown-adipocyte-like phenotype
through transdifferentiation processes to respond to a variety of stimuli, including diet or
exercise training (ET) [5–7]. The WAT, usually referred to as periprostatic adipose tissue
(PPAT), surrounds the prostatic gland and contributes to tumor microenvironment (TME)
modulation once PCa cells invade periprostatic adipose tissue (PPAT) [8,9]. The PPAT
appears to be involved in signaling pathways that influence PCa progression, emphasizing
pivotal roles for WAT and obesity in PCa [10,11]. Increased local and systemic inflammation
and fatty acid (FA) availability and the dysregulation of insulin and growth factor (GH),
the insulin-like growth factor (IGF)-1 axis, sex steroid hormones, and adipokine synthesis
and secretion [12] have emerged as possible mechanisms that could underpin the complex
and intricate crosstalk between PPAT and PCa.
Skeletal muscle is a highly malleable tissue that has a notorious impact on the whole-
body metabolism [13]. A loss of skeletal muscle mass and strength apparently impacts
cancer survival, not only through physiologic and metabolic-related mechanisms, but also
through behavioral aspects, e.g., reduced physical activity levels due to deconditioning
and fatigue imposed by cancer treatments [14]. Exercise training (ET) induces several adap-
tations in both skeletal muscle and WAT that likely result in protective effects on metabolic
and inflammatory features that typically characterize obesity and cancer diseases [5,7,15,16].
Moreover, ET promotes the synthesis and secretion of several factors known as myokines
(when released by skeletal muscle) or adipokines (when released by WAT). Together, they
likely act in an endocrine-dependent manner to favor the communication between skeletal
muscle and WAT [17,18], as they likely work in partnership to improve whole-body health.
This crosstalk may constitute a potential mechanism by which ET exerts its beneficial roles
in the prevention and treatment of PCa-related disorders; however, this question has not
been explored.
Therefore, in the present review, we focus on the current evidence on the effects of
skeletal muscle–adipose tissue–tumor crosstalk in PCa and the potential mediators of this
process in an attempt to determine the underlying ET-related mechanisms. A special box
briefly describes cancer-induced cachexia in obesity (Box 1).
2. Prostate Cancer and Obesity
PCa is the second most frequently diagnosed cancer and the sixth most common cause
of cancer-related mortality among men worldwide. Obesity has been established as a major
risk factor for several cancers, including PCa [19,20]. Concerning the epidemiological
association between obesity and PCa, the related body of evidence strongly suggests that
excessive visceral adiposity represents a major risk factor for developing more aggressive
disease and a higher PCa-specific mortality [3,21]. Nevertheless, controversies exist, par-
ticularly due to studies that have used body mass index (BMI) as a proxy for adiposity.
Findings from meta-analyses [3,19,22,23] have demonstrated a weak association between
BMI and PCa aggressiveness [23,24]. Considering that the BMI may also reflect increased
lean fat mass (e.g., bone, muscle), other anthropometric parameters, such as waist circum-
ference (WC) and waist–hip ratio (WHR) have been reported to be more consistent [3,25].
Both WC and WHR, in combination with BMI or not, seem to be more accurate indicators
of WAT distribution [3,25].
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Thus, the increase in WAT mass is responsible for the development of several obesity-
related complications when white adipocyte hypertrophy is accompanied by an inadequate
supply of nutrients, growth factors, and oxygen [26,27]. In this context, a set of events
may occur at the WAT and other tissues in contact with it, including hypoxia, apoptosis,
immunoinflammatory upregulation, extracellular matrix remodeling, and metabolic and
endocrine dysregulation [28–31]. Taken together, these events might favor tumorigene-
sis [2]. Although the association between obesity and PCa has been supported by several
studies [3,23–25], understanding and demonstrating the causal biological mechanisms
remains unaccomplished.
2.1. Obesity-Induced Periprostatic Adipose Tissue Modifications
The human prostate gland is surrounded by periprostatic adipose tissue (PPAT) that
lies directly adjacent to the prostatic capsule [32]. According to its anatomic localization,
it is noticeable that the surrounding microenvironment of PPAT influences the prostatic
gland [8,9]. Greater PPAT areas and thicknesses, which are influenced by age and body
composition, have been shown to be associated with PCa aggressiveness [33,34]. Thus, in
this adipocyte-rich microenvironment, namely when tumors contact the prostatic capsule,
likely promotes cancer growth, adipocytes and obesity have a pivotal role in PCa tumor
aggressiveness [10,11]. Extracapsular extension is a well-appreciated factor that is involved
in PCa aggressiveness, local dissemination, and recurrence [35]. Therefore, the complex
and intricate crosstalk between PPAT and PCa cells is likely to shape the prostate TME and
might be responsible for more aggressive PCa behavior. The previously described role of
PPAT in PCa reveals the prominent impact of local WAT deposits in tumor progression,
even beyond global adiposity measures.
2.1.1. Bidirectional Paracrine Signaling
Several different types of carcinoma are known to invade adjacent WAT, leading to
crosstalk between adipocytes and malignant cells. The reciprocal interaction between
cancer cells and adipocytes is highlighted by the reprogramming of adipocytes to a dedif-
ferentiated status, termed cancer-associated adipocytes (CAAs) [11]. CAAs delipidation
is accompanied by the secretion of inflammatory cytokines and proteases that fuel the
rapid growth of neighboring cancer cells and prompt a tumor-permissive niche, promoting
tumor growth and metastasis [11,32,36]. In PCa, periprostatic adipocytes promote the extra-
capsular invasion of PCa by secreting CCL7 and stimulating the migration of CCR3+ tumor
cells. Obesity upregulates the secretion of CCL7, contributing to increased extraprostatic
extravasation and dissemination. Accordingly, a high level of CCR3 expression in PCa is
associated with extended dissemination and aggressive disease [35]. Moreover, PPAT from
obese patients has been proven to secrete increased amounts of matrix metalloproteases
and to promote both the survival and migration of PCa cell lines [9].
Notwithstanding, the influence of WAT on tumor initiation and progression goes
beyond adipocyte-specific interactions. The adipose stromal compartment also plays a
critical role in cancer development. Mesenchymal adipocyte precursors, termed adipose
stromal cells (ASCs), have also been implicated in cancer. Given the rising numbers of
ASCs in the PPAT of obese PCa patients [9,37], it is apparent that these cells contribute
to the obesity-cancer relationship. In an obesity-driven mouse model of myc-induced
PCa, the increased expression of CXCL12 from ASCs promotes the homing of CXCR4+
and CXCR7+ cells to the PPAT [38]. The CXCL12/CXCR4 axis has been implicated in
the recruitment of both local adjacent and distant ASCs, showing that distant adipose
depots have a critical role in PCa [39]. In addition, the inactivation of CXCL12 in ASCs
was shown to preclude tumor growth and the epithelial to mesenchymal transition in
Myc-driven murine PCa models [40]. Importantly, ASCs can be recruited to the TME
from adjacent or distant adipose depots via chemokine gradients [41]. ASC trafficking to
prostate tumors was demonstrated to be dependent on the production of CXCL1 and IL-8
to chemoattract CXCR1+ and CXCR2+ ASCs. In fact, under conditions of obesity, PCa
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display increased expression of CXCL1 and IL-8 chemokines, promoting the homing of
ASCs to the tumor microenvironment and contributing to tumor growth promotion [42].
Infiltrating ASCs, upon arrival, contribute to a series of tumor-promoting processes that
include the recruitment of macrophages and T lymphocytes to the TME and the promotion
of angiogenic pathways. In fact, ASCs recruited to the tumor stroma are capable of
differentiating into different cell types, including adipocytes, fibroblasts, and pericytes,
depending on the environmental cues and tumor needs, providing another route for cancer
progression and metastasis [41,43,44].
2.1.2. Fatty Acid Availability and Metabolic Adaptations
Metabolic reprogramming is now widely considered to be a decisive process that
supports the malignant properties of cancer cells [45]. In fact, tumor cells often change
their metabolic status, generating adenosine triphosphate via glycolytic processes rather
than oxidative phosphorylation, even under aerobic conditions, through a process known
as the Warburg effect or aerobic glycolysis [45,46].
Cancer metabolism is heterogeneous and highly dependent on the TME cues and
characteristics of the tissue of origin [47,48]. Importantly, unlike other solid tumors that
are largely considered to be highly reliable on glycolysis, PCa metabolism is thought to be
less glycolytic, while increases mitochondria oxidative phosphorylation and lipogenesis
drive tumor progression [49,50]. Notably, androgen-receptor-mediated metabolic repro-
gramming increases the mitochondrial respiratory rate and de novo lipid synthesis [51].
However, the Warburg effect has been observed in the treatment of advanced PCa, specifi-
cally in metastatic tumors, which makes glucose-derived chemotherapeutics a promising
treatment for this type of PCa [52].
It is becoming increasingly clear that the heterogeneity of cancer metabolism depends
on both intrinsic cancer cell factors and other factors imposed by the tumor landscape [53].
For instance, lactate derived from glycolytic processes in hypoxic cancer cells is leveraged
by well-oxygenated neighboring cancer cells to produce energy via oxidative phospho-
rylation, underlying metabolic symbiosis that is mainly controlled by hypoxia inducible
factor (HIF)-related components through the regulation of glucose and lactate transporters
in different cancer populations. [45,53,54]. On the other hand, tumors surrounding non-
transformed cells may support tumor growth [55]. Notably, cancer-associated fibroblast
catabolic processes “feed” anabolic cancer cells [12].
Lipid-filled adipocytes are found in the vicinity of tumors, and the reciprocal crosstalk
between these cells leads to profound metabolic alterations that result in the release of
free FAs from the adipocyte compartment to sustain tumor growth [56]. This metabolic
symbiosis demonstrates that energy transfer occurs in cancer cells and is metabolically
able to reprogram both local and distant tissues, including PPAT [12,57]. The survival-
promoting effect of cancer-associated adipocytes relies on the capability of these cancer-
modified adipocytes to provide nutrients to tumor cells, sustaining growth and survival and
promoting metastatic behavior [58–60]. This impact has been evidenced by the ability of
PCa cells to induce a cancer-associated adipocyte phenotype in vitro and in vivo, reflecting
a more invasive phenotype [9]. This aggressive phenotype is also ensured by the induction
of oxidative stress in a nicotinamide-adenine dinucleotide phosphate oxidase-dependent
manner [9].
Hypoxia leads to increased lipid usage by cancer cells and lipid metabolization, which
is a feature of several human cancers, including PCa [61–63], since it provides the necessary
energy for cancer growth [64]. FAs are the main source of lipids used by cancer cells. The
use of FAs to produce energy via FA oxidation increases the energetic yield compared
with other energy sources [65,66]. Notably, malignant cells are capable of synthesizing
FAs de novo, even in the presence of exogenous FA sources. In fact, in fast growing
tumors, endogenous lipogenesis becomes limiting, and transformed cells increase their
extracellular FA uptake [67]. The lipolytic state induced by cancer cells on neighboring
adipocytes increases the FA availability and fulfils the energetic needs of the demanding
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and expanding tumor mass [36,57]. Fatty acid-binding proteins (FABPs) mediate the
trafficking of adipocyte-derived FAs toward cancer cells. In fact, FABP4, mainly expressed
in adipocytes, has already been shown to mediate this transport. In turn, cancer cells
upregulate the expression of FA transporters (e.g., cluster of differentiation 36 (CD36)),
increasing the influx of FAs and providing the tumor with sufficient substrates to sustain
growth and progression [68]. In PCa, extracellular FAs seem to be crucial contributors
to lipid synthesis and tumor progression [69], and the inhibition of FA uptake by CD36
abrogation has been demonstrated to be an effective strategy to reduce tumor growth
in preclinical models of PCa [70]. Therefore, adipocyte-derived FAs might constitute an
important substrate to support tumor growth and metastasis. Disabling FA uptake by
cancer cells and targeting lipid metabolism are important ways to improve therapies and
tailor novel therapeutic approaches.
2.1.3. Obesity-Driven Inflammation
Inflammation is a hallmark of cancer and a critical link in obesity-driven cancer
initiation and progression [43,45]. The unbalanced energy intake associated with WAT
hypertrophic growth generates surplus lipid accumulation, leading to alterations in in-
sulin sensitivity and mitochondria functioning [71]. This condition triggers a series of
defective neoangiogenic mechanisms and a consequent hypoxic environment that leads to
a sustained low-grade chronic inflammatory state [71–73]. Chronic inflammation repre-
sents a prolonged and dysfunctional protective mechanism in response to a loss of tissue
homeostasis and emerges as a driving mechanism for cytotoxic accumulation of reactive
oxygen and nitrogen species, leading to genomic instability [44,45,74]. In lean individuals,
WAT immune infiltration maintains tissue homeostasis, contributing to the clearance of
apoptotic cells, angiogenic regulation, and extracellular matrix remodeling, preserving
the balance of the microenvironment. On the other hand, adipocyte death, tissue hypoxia,
and mechanical stress induced by obesity [27,75] promote the recruitment and immune
cell phenotypic reprogramming toward a proinflammatory profile that contributes to
a sustained inflammatory state [76]. Notably, the hypoxic microenvironment induced
by obesity contributes to immune cell exhaustion, increasing the expression of immune
checkpoints such as programmed cell death-ligand 1 (PDL1 or CD274) and its receptor,
programmed cell death protein 1 (PD1 or CD279), on tumor-associated macrophages and T
cells, respectively, via HIF-1α, suppressing immunosurveillance [77–79].
WAT hypoxia upregulates the secretion of proinflammatory cytokines, namely tumor
necrosis factor (TNF)-α, interleukin (IL)-1β, IL-6, and monocyte chemoattractant protein
(MCP)-1, providing a tumor-permissive niche for transformed infiltrating cells [31,80,81].
Macrophages accumulate in the vicinity of dying adipocytes and create phagocytic im-
mune aggregates, termed crown-like structures, and scavenge lipids and cellular debris,
which additionally exacerbates systemic and local inflammatory states with a high level
of production of proinflammatory cytokines [41,82,83]. Importantly, the presence of
crown-like structures has been associated with a higher prostate tumor grade in men
diagnosed with PCa [84]. Obesity increases the ratio of M1 pro-inflammatory to M2a anti-
inflammatory macrophages by enhancing the recruitment of C-C chemokine receptor type
2+ pro-inflammatory macrophages [85]. Moreover, obesity contributes to the enrichment of
WAT-educated helper and cytotoxic T cells through the additional aggravation of inflam-
matory mechanisms by secreting matrix metalloproteinases, vascular endothelial growth
factor (VEGF), TNF-α, IL-6, MCP-1, and IL-1β, therefore leading to an obesity-driven
inflammatory state [43,76,86,87].
This inflammatory environment helps to sustain pro-tumorigenic activities [88]. In
fact, IL-1β has been shown to promote PCa progression through the repression of androgen
receptor expression and promotion of the adaptor protein p62, a partner required for
nuclear factor kappa B induction of cancer cell proliferation, invasion, and metastasis [89].
Convincing results have been obtained for IL-6 whose roles in PCa initiation, progression,
and prognosis have been supported by several studies [88,90–92]. The level of IL-6 in
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PPAT was approximately 375 times greater than that observed in patient-matched serum.
Additionally, the level was correlated with the pathological grade [92]. These findings
demonstrate that there is greater phosphorylation on the signal transducer and activator of
transcription 3 in high-grade tumors (any component of Gleason score 4 or 5) [92]. IL-6
has been suggested to be an oncogene in PCa that upregulates insulin growth factor (IGF)
signaling [28], reprograms prostate gene expression, and drives PPAT inflammation [93].
2.1.4. Adipokines
A recent study contributed an important clue to PCa pathology using liquid chrom
atography-mass spectrometry-based proteomic analysis in PPAT-conditioned media [94].
Some adipokines, such as IL-6, adiponectin, and chemokine (C-C motif) ligand 7, were
found to be associated with PCa TME, while results for other factors are controversial. In
this context, the leptin concentration of PPAT was not found to be correlated with PCa
aggressiveness in a series of 30 PPAT samples obtained from patients who underwent
radical prostatectomy [2]. Recent evidence suggests an association between leptin and
PCa [95]. The level of adiponectin decreased in PPAT exposed to PCa-conditioned media [8],
suggesting an inverse association between adiponectin and the incidence of advanced PCa.
The role of adipokines on PCa requires further investigation.
Other adipocyte-secreted factors that have been pointed out, like TNF-α and VEGF,
were found to be associated with high-grade PCa in a small series of 69 patients who
underwent radical prostatectomy [34]. On the other hand, vascularization of the prostate
crosses PPAT and favors molecular exchanges between PPAT and cancer cells [96]. The
expression of osteopontin, a pro-metastatic protein involved in inflammatory and immune
responses, was shown to be increased in human PPAT following PCa-conditioned media
treatment [32].
2.1.5. Sex Steroid Hormones
Sex steroid hormones have important roles in the function of the prostate and may
also serve as a factor in the initiation and progression of carcinogenesis [29]. Obesity or
the presence of a hyperinsulinemia state likely contributes to a slow decrease in estradiol
levels, but this is not always to the same extent given the moderating effect of increased
peripheral aromatization [30]. Obesity is a key regulator of systemic sex steroid levels
through the peripheral conversion of testosterone to estrogens via aromatase in WAT [29].
Prostate epithelial cells require androgens both for normal physiology and during
malignancy development. Androgen deprivation therapy (ADT) is the primary systemic
treatment for hormone responsive advanced PCa, but it seems to also have an interesting
role in the earlier stages of disease [97]. Men receiving ADT suffer from muscle mass loss
and strength, anemia, sexual dysfunction, and accelerated bone loss and fractures [97].
Interestingly, ADT is associated with a proinflammatory and obesity-like PPAT microenvi-
ronment with adjacent effects in the PPAT [88]. In ADT-treated patients, the PPAT showed
a transcriptomic pro-inflammatory signature, characterized by the up-regulation of IL-
6/janus tyrosine kinase/ signal transducer and activator of transcription 3 pathway, the
increase of interferon gamma response, and the increment of macrophages within PPAT [88]
These findings seem to be relevant for localized disease, whereas further characterization
of this fat depot in later stages of disease is lacking, particularly phenotyping the PPAT
immunological environment. Cancer-induced cachexia is discussed in Box 1.
Int. J. Mol. Sci. 2021, 22, 4469 7 of 21
Box 1. Special box—Cancer-induced cachexia.
Cancer-induced cachexia (CiC) is a multifactorial syndrome characterized by a progressive loss
of body weight, mainly the loss of skeletal muscle and/or WAT mass through energy imbalance [98],
representing a well-known component of cancer [99]. Although PCa has the lowest prevalence
of CiC and lower rates of weight loss compared with other types of cancer [100,101], it is the
most commonly diagnosed cancer in males worldwide [1]. CiC has important implications on
skeletal muscle quality, both in terms of tissue quantity and functionality, which leads to progressive
overall functional impairment [99,102] and is responsible for more than 20% of cancer deaths [99].
Considering only body weight, CiC and obesity may seem to be opposing diseases. However,
obesity also induces severe muscle depletion, known as sarcopenic obesity, which is an independent
risk factor for overall survival in several types of cancer [103,104], particularly in PCa [105]. In
fact, both CiC and obesity share several underlying mechanisms that lead to severe skeletal muscle
atrophy [106]. Concurrent gain of WAT and loss of skeletal muscle also occur during ADT [107,108],
highlighting not only the importance of maintaining the skeletal muscle quality but also the clinical
significance of adiposity, irrespective of CiC.
Among the therapeutic interventions available to mitigate the overall progress of CiC, ET
appears to have a significant impact on the skeletal muscle–adipose tissue–tumor axis [109]. The
effects of ET on the preservation of muscle mass and force in an animal model of PCa have been
reported [110]. In this study, a 20-week period on the free wheel was able to prevent skeletal
muscle loss by diminishing myostatin concentrations in the skeletal muscle of a transgenic mouse
prostate adenocarcinoma model. Myostatin has been described to trigger catabolic activity in
the skeletal muscle by downregulating protein kinase B signaling and stimulating SMAD2/3
signaling, inducing increased protein degradation and muscle wasting (for a review, see [111]).
Decreased myostatin signaling in response to ET suggests that exercise not only protects against
muscle loss by preventing atrophy but also promotes positive protein turnover [110]. Although the
pathophysiology of sarcopenia and muscle wasting is multifaceted, skeletal muscle must be seen as
a tissue of clinical relevance that can counteract the deleterious effects of both CiC and sarcopenic
obesity [112].
3. Exercise Training as an Intervention for Obesity and Prostate Cancer
ET is one of the most powerful lifestyle strategies used to prevent and/or miti-
gate against becoming overweight and/or the visceral adiposity accumulation associated
with obesity [113,114]. Even when body weight is not reduced, ET has a significant im-
pact on metabolic health [114]. Accumulating evidence reveals that ET can counteract
metabolic and inflammatory features usually observed in central adiposity, strengthening
the metabolic relevance of WAT on whole-body adaptations to ET and revealing a promis-
ing direct target in the treatment of obesity and associated disorders [5,6,115]. In this sense,
the modulation of PPAT by ET is of utmost importance for its implications in the TME of
PCa patients; however, to the best of our knowledge, no research has directly addressed
this question.
Studies conducted in PCa patients have shown that ET is an important strategy that
can be used to mitigate PCa-related clinical features, such as lower circulating glucose and
insulin levels, increased adipose tissue mass, and whole-body inflammatory markers as
well as improving hormonal levels [15,16,108]. Furthermore, the impact of ET in skeletal
muscle was observed by inducing phenotypic alterations mediated by transcriptional
responses that occur during and following an exercise session [7]. Some genes, such
as GRIK2, TRAF1, BICC1, and STAG1, are epigenetically sensitive to acute bouts of ET,
maintaining an hypermethylated state for up to 22 weeks of detraining [116]. This repeated
and transient increase in the expression of ET-responsive genes in skeletal muscle confers
ET adaptations over time and, thus, contributes to a better understanding of the benefits
widely reported in specific populations [117–120].
3.1. Aerobic Exercise
Aerobic exercise promotes the ability to perform moderate to vigorous ET within the
abilities of the respiratory, cardiovascular, and muscular systems to integrate physiological
and functional states for a prolonged period of time [121], which can be accessed via aerobic
capacity [122]. A poor aerobic capacity has been associated with a markedly increased risk
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of premature death [123] and the development of several non-communicable diseases [124],
including cancer [125]. In contrast, a high aerobic capacity is associated with a protective
effect against cancer specific mortality, cancer recurrence, and/or all-cause mortality [126].
Data from prospective population-based studies [127,128] and systematic review and meta-
analysis studies [129,130] have revealed an inverse association between advanced PCa risk
and physical activity, demonstrating a potential protective role of regular physical activity
against the risk of aggressive disease. After diagnosis, self-reported physical activity (>3 h
per week at high-intensity) was found to reduce the risk of PCa-specific mortality and
recurrence [131] compared with men who completed less than 1 h per week of vigorous
activity. These findings suggest that physical activity counselling has a positive impact on
PCa patients. Moreover, data from the Cancer of the Prostate Strategic Urologic Research
Endeavor [132] showed that walking duration and total non-vigorous activity were not
associated with risk of progression, but brisk walking may inhibit or delay PCa progression
among men diagnosed with clinically localized PCa. In the light of these results, ET
intensity may be a crucial factor in decreasing the risk of disease aggressiveness. However,
others have found no relationship between ET and PCa risk or aggressiveness [133].
In a cross-sectional study, muscle mass, size, and strength were found to be com-
promised in PCa patients treated with ADT [134]. A 12-week cycle ergometer program
performed at 65–75% of maximal oxygen consumption (V̇O2max) was shown to influence
peripheral tissue insulin sensitivity, visceral adiposity, skeletal muscle protein content
of glucose transporter type 4 (GLUT4), and total protein kinase B in both PCa patients
undergoing ADT and non-exercise groups [15]. These findings suggest that the testos-
terone ablation in men did not constitute an impediment for peripheral tissue to increase
insulin sensitivity in response to ET, which suggests that the insulin signaling cascade is a
potential underlying molecular mechanism. Hence, these effects may result from exercising
in general, and not from aerobic exercise specifically, as PCa patients undergoing ADT had
very similar adaptations to healthy men in response to the same ET program. Furthermore,
the benefits of ET extend to other aging-related comorbidities or cancer treatments side
effects. For example, patients with PCa exposed to ADT were shown to have an increased
risk for developing cardiovascular disease, which could be attenuated by regular ET [16].
Regular aerobic exercise induces alterations in DNA methylation patterns in the skele-
tal muscle, specifically with respect to genes associated with muscle growth, differentiation,
and metabolism [135]. The skeletal muscle miRNA expression kinetics in response to
aerobic exercise are less dependent on variables such as age, a specific ET regimen, or ET
history compared with resistance exercise. However, one of the best-characterized genes
that is upregulated in response to aerobic exercise and contributes to metabolic adaptation
is the peroxisome proliferator-activated receptor gamma coactivator (PGC)-1α gene [136].
As recently reviewed by Neil-Sztramko et al. [137], the dosage of ET (volume, intensity
and frequency) against cancer-specific mortality, recurrence, and/or all-cause mortality in
PCa patients is still scarce. Few studies have appropriately reported four or five principles
of ET, such as specificity, progression, overload, initial values, and diminishing returns.
Therefore, a lack of attention to the principles of ET may result in underestimation of
the real effect of ET and/or leave a gap in the information required for prescribing an
ET program.
3.2. Resistance Exercise
Resistance exercise can be characterized as voluntary contractions against an external
load. It is typically performed with specifically designed equipment, free weights, and/or
elastic bands [138], although it can also be performed using bodyweight as resistance [139].
Resistance exercise is widely recognized as a key strategy to promote beneficial effects for
the average population, such as reversing muscle loss, reducing body fat, and improving
physical function and mental health [140,141]. Resistance exercise has an important role
in decreasing the risk of nonfatal and total cardiovascular disease events [119]. In some
specific populations, such as elderly [120], diabetic [118], or cancer patients [142], resis-
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tance exercise plays an important role as a safe and effective strategy to improve body
composition as well as increasing skeletal muscle mass and strength.
Even if muscle hypertrophy and strength gains are commonly associated with each
other, it should be noted that adaptations may vary according to individuals’ genetic
characteristics [143] and/or the selection of programming methods [144]. Mechanical
tension is a key variable in the aforementioned neuromuscular adaptations and is mainly
influenced by training load and time under tension [145], triggering a series of intracellular
processes that regulate gene expression, increase protein synthesis [146], and enhance
cellular responses in myofibers and satellite cells [147]. Exposure to this type of regular
stress, i.e., mechanical and/or metabolic tension, promotes muscle damage, an important
mediator for increasing muscle mass [145]. These myotraumas initiate acute inflammatory
responses and activate the production of myokines, resulting in the release of growth
factors that stimulate satellite cell activity and, thus, muscle hypertrophy [145,148]. The
hypertrophic response relies mainly on anaerobic glycolysis for energy production, which
promotes increased secretion and production of hormonal factors as well as the activity of
growth-oriented transcription factors [149].
Although DNA methylation patterns are significantly altered in exercising skeletal
muscle, these alterations are of high importance for cell function under both physiological
and pathological conditions [136]. When exposed to resistance exercise, the mechanis-
tic/mammalian target of rapamycin complex 1 pathway is known as one of the central
players that mediates transcriptional changes, affecting a broad variety of genes [136].
Gene expression is regulated by miRNAs—small endogenous, single stranded, non-coding
RNAs that are regulated by ET. After their identification, their potential to be used as
novel diagnostic and prognostic biomarkers has increased substantially, as they have been
associated with improvements in markers of cardiovascular disease, cancer, diabetes, and
other pathologies [150]. The degree of individual adaptations, including DNA methylation
and gene expression via specific miRNAs without altering the DNA base, known as the
individual’s epigenetic “signature”, is based on previous ET history and the ET regimen
(aerobic or resistance) [136,151].
As mentioned in the special box, PCa patients can experience several cancer-treatment-
related adverse side-effects, such as the loss of skeletal muscle mass and strength, which
usually results in increased bone frailty and a high fracture risk [152]. Given that the in-
crease of skeletal muscle mass is a well-known factor in the maintenance and enhancement
of strength capacity [153], it is vital to identify muscle-hypertrophy-related mechanisms
to better understand how resistance exercise induces skeletal muscle adaptations. A few
studies conducted in PCa patients have provided an idea of the effects of unimodal ET
interventions. In one study, men undergoing ADT performed a resistance exercise program
for 20 weeks (6- to 12-repetition maximum) [154]. They experienced significant improve-
ments in skeletal muscle strength and endurance as well as in functional tasks (e.g., chair
rise, 6-m walk) without changes to fat mass, prostate-specific antigen, testosterone, growth
hormone, cortisol, or hemoglobin. Since this was an observational study, it is not possible
to state that the effects were specifically due to resistance exercise or to exercise in general.
In a randomized study with 58 PCa patients undergoing ADT while participating in
a 16-week resistance exercise program (three weekly sessions) or usual care [155], it was
observed that no significant effects on total lean body mass in either group. Nevertheless,
variations in lean body mass in the upper and lower limbs reduced significantly (by
0.49 kg and 0.15 kg, respectively). In the same study, PCa patients undergoing ADT were
shown to have greater strength and functional test scores (e.g., stair climbing), although
no benefits on fat mass, BMI, or quality of life were found compared with the usual care
group. However, the absence of a contrasting ET modality raises concerns as to whether
any effects were due to resistance exercise or to exercise in general.
A systematic review and meta-analysis assessed the effects of resistance exercise on
health and fitness parameters in PCa patients [142]. Generally, the majority of resistance
exercise-based programs showed promising results with significant improvements in
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upper and lower body strength, body fat percentage, lean body mass, trunk fat mass,
and cardiorespiratory parameters. It should be noted that the studies included both
ADT-treated and non-ADT-treated patients.
Globally, most randomized control trials have used a combination of aerobic and
resistance exercises (ranging from two to five sessions per week) and shown improvements
not only in functional performance tasks (e.g., 400 m walk test) but also in metabolic pa-
rameters (e.g., diastolic blood pressure, fasting blood glucose) and body composition [156].
Conversely, these markers have shown heterogeneous responses across trials, and those
effects have mostly been derived from a small subset of studies, as examined by Bourke
et al. [156]. It should be noted that although these statistical differences were detected, their
translation into clinically relevant improvements remains elusive.
3.3. High-Intensity Interval Training
High-intensity interval training (HIIT) involves repeated bouts of high-intensity effort
followed by varied recovery times [121] with promising data for enhancing physical
fitness. It is recognized as a time-efficient exercise modality that overcomes the barrier
of lack of time [157]. Studies on feasibility, safety, and the acute and chronic responses
of cancer patients to HIIT in cancer patients are still scarce. A meta-analysis showed
that HIIT is an effective training type compared to moderate and continuous ET that
induces similar or higher systemic and tissue changes, including effects on V̇O2max, cardiac
function, mitochondrial capacity, oxidative stress or inflammation, and the perception of
enjoyment [158].
In forty cancer survivors (20 breast and 20 PCa survivors), two cycle ergometer HIIT
protocols (10 × 1 min at peak power output (10 × 1) and 4 × 4 min at 85–95% peak HR
(4 × 4)) were demonstrated to be safe strategies after the end of primary therapy [157].
Ninety-five percent of participants completed the HIIT protocol. The authors observed that
the estimated energy expenditure, heart rate, and blood lactate concentration were higher
in the 4 × 4 min at 85–95% peak heart rate vs. The 10 × 1 min protocol [157]. It should be
noted that if a higher training stimulus is intended, the 4 × 4 protocol is more appropriate.
In PCa patients undergoing radiotherapy, short-term participation in HIIT on the
cycle ergometer (8–15 × 60 s intervals at ≥85% maximal heart rate, 3 sessions per week)
increased the functional exercise capacity assessed by the 6 min walk test and counteracted
cancer-treatment-related fatigue compared with the usual care group [159]. Thus, HIIT
may be an optimal exercise prescription for improving various aspects of health that are
typically impaired in PCa patients; however, further investigation is needed.
3.4. Skeletal Muscle–Adipose Tissue–Tumor Axis: Molecular Mechanisms Linking Exercise
Training in Prostate Cancer
The skeletal muscle may act as an energy storage site that can be used in strongly
catabolic periods, such as during cancer or cancer treatments [160]. A greater skeletal
muscle mass may assist in improving cancer-related outcomes [161]. Indeed, ET has been
largely used as an adjunct therapy for PCa patients [16], even though the isolated effects of
ET are not completely understood [162].
Beyond the general role of adiposity in the overall body composition [163], skeletal
muscle can actually display excess WAT deposits, a phenomenon known as myosteatosis,
which is negatively linked to health outcomes [164]. Myosteatosis has been proposed as a
prognostic biomarker in patients undergoing radical cystectomy [165] and in those with
endometrial cancer [166]. While a greater muscle cross-sectional area is prognostic of lower
mortality rates in older patients with cancer [167], its role may vary depending on the
degree of myosteatosis present [168]. Indeed, patients with similar levels of skeletal muscle
mass but distinct amounts of intramuscular WAT deposits are likely to experience greater
levels of toxicity in response to chemotherapy [169].
Myosteatosis is apparently derived from enhanced local secretion of inflammatory
adipokines which, in turn, may be indicative of increased insulin resistance [164]. In addi-
tion, intramuscular WAT accumulation may impair blood flow within the skeletal muscle,
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further aggravating insulin resistance [164] and stimulating neoplasic outgrowth [170]. Ac-
cordingly, it is possible that ET improves nitric oxide bioavailability, which would improve
myocardial function and peripheral blood flow [162]. In general, chronic ET may also
improve endogenous antioxidant pathways [171], potentially conferring extra protection
against cancer development.
Overall, ET may have distinct effects on cancer through sarcopenia and myosteatosis
in breast and PCa patients. Patients who regularly exercise showed improvements in these
two factors, which are independent prognostic factors of treatment outcomes [168,169].
However, greater consensus should be achieved regarding which cut-off values for clas-
sifying active or non-active subjects may be more appropriate for both health and/or
specific cancer populations. Alternatively, the skeletal muscle index and density may be
combined into a skeletal muscle indicator value [168], although future research is required
to understand the full applications and limitations of this index. The widely recognized
profits from systematic ET programs [141] with low risks and high benefits, together with
the ability to increase lean muscle mass and bone density, support its usage in PCa patients
undergoing ADT [162].
3.4.1. Effects of Exercise Training on the Tumor Microenvironment
ET has been shown to lack an impact on tumor growth, although it has been associated
with increased tumor vascularization and a shift toward reduced metastasis in an orthotopic
model of murine PCa [172]. In an in vitro study, it was observed that androgen dependent
LNCaP cell lines cultured in serum from exercised subjects grew less than in a control
group by limiting proliferation and cell cycles [173]. In addition, exposure to post-exercise
serum resulted in a >350% increase in cancer cell apoptosis through upregulation of the
pro-apoptotic p53 protein.
Mice subcutaneously implanted with LAPC-4 PC were randomly assigned to volun-
tary wheel running or a non-intervention control group [174]. The voluntary exercised
mice exhibited less tumoral necrosis, together with a ~150% increase in the microvessel
density, indicating the relevant role of ET as a potential intervention to inhibit PCa growth
and its underlying biologic mechanisms.
Therefore, studies assessing the optimal dosage and modality of ET in PCa patients are
required [142]. In this context, eccentric exercise should be included in future research once
it has been demonstrated to be a powerful ET modality in critically ill patients [175,176].
3.4.2. Effects of Exercise Training on Inflammation
Clinical data regarding the effects of ET on systemic inflammation are not straight-
forward. In non-cancer patients, strenuous ET bouts and heavy training loads have been
shown to modify T-cell immunity towards an anti-inflammatory state by increasing the
numbers of resting peripheral blood type-2 and regulatory T-cells, which produce mainly
the anti-inflammatory cytokines IL-4 and IL-10, respectively [177,178]. Nevertheless,
12 weeks of ET did not affect the systemic concentrations of TNF-α, IL-6, plasminogen
activator inhibitor-I, leptin or adiponectin, although a reduction of visceral adiposity was
observed in PCa patients receiving ADT [15]. The effects of ET on systemic inflammation
possibly depend on its baseline levels and, therefore, affect people distinctly. Moreover,
obese patients experience poorer outcomes during and after PCa treatments. Under these
conditions, ET may be especially helpful for these patients [179].
3.4.3. Effects of Exercise Training on Skeletal-Muscle-Derived Myokines and Impacts on
Adipose Tissue
The metabolic disturbances typically observed in PCa patients receiving ADT suggest
that skeletal muscle–adipose tissue–tumor crosstalk may represent an important opportu-
nity to investigate the mechanisms underlying a loss of anabolic signals, sarcopenia, and
frailty, and overall, they may contribute to metabolic dysregulation [97,107]. Additionally,
the promyogenic anabolic interventions associated with increased skeletal muscle mass
have been described as a potential strategy to improve cardiometabolic outcomes in PCa
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patients receiving ADT [15]. Thus far, to the best of our knowledge, this question has been
poorly investigated.
Mechanistically, the contracting skeletal muscle locally stimulates several signaling
pathways involved in its morphology and metabolism and produces and secretes bioactive
molecules—myokines—which act in an endocrine-like fashion in distant tissues [13], such
as WAT [180]. ET-associated skeletal-muscle-derived myokines may influence the metabolic
phenotype of WAT by inducing a brown-adipocyte-like phenotype and thus improving FA
oxidation and insulin sensitivity [7,181]. Therefore, myokines likely provide a conceptual
basis to understand, at least in part, the modulatory impact of ET on WAT, e.g., the crosstalk
in the skeletal muscle–WAT axis, which is of particular interest in both obesity and cancer
settings. Accordingly, several studies have focused on myokines released from skeletal
muscle during and immediately after ET, such as IL-6, -8, and -15, among others [7,13]. The
cleaved product of fibronectin type III-domain containing 5 (FNDC5), a PGC-1α-dependent
myokine, is secreted into the circulation, designed as irisin, and has the ability to initiate a
brown-adipocyte-like phenotype program in WAT [18]. Undifferentiated white adipocytes
treated with FNDC5 in vitro were shown to overexpress UCP1-positive cells and increase
mitochondrial density and gene expression concomitantly with increases in V̇O2, heat loss,
and energy expenditure [17]. These cells are metabolically more active, which may be
advantageous in obesity and/or cancer contexts. However, to the best of our knowledge,
this mechanism has been extensively reported for WAT depots but not for PPAT.
IL-6 is a proinflammatory cytokine expressed in tumors and in the stroma TME [90],
but it is also a myokine prototype [182]. Indeed, circulating levels of IL-6 were found
to be acutely elevated in response to ET [13]. Therefore, IL-6 has the ability to promote
metabolic alterations in the skeletal muscle itself as well as in other organs, including
WAT, in an endocrine manner [13]. The beneficial endocrine effects of increased IL-6
levels in response to ET on WAT have been postulated to be related to increases in the
activity of adenosine monophosphate-activated protein kinase (AMPK), an energy-sensing
enzyme [182–184]. Considering that an increase in the IL-6 concentration correlates tempo-
rally with increases in AMPK activity, some studies have suggested that IL-6 is involved in
AMPK activation during the later stage of ET when the energetic state of skeletal muscle is
lower [183,184]. Furthermore, the phosphorylation/activation of AMPK has been proposed
to be ET intensity-dependent [7,185]. Pre-clinical studies have found that AMPK has partic-
ularly relevance in certain primary tumors, including PCa. Chippa et al. [186] reported that
both androgen deprivation and hypoxia induce AMPK activation in androgen-dependent
cancer cells, which is required to initiate cells to undergo autophagy, prolonging their
survival; however, further research in this area is warranted.
The impact of ET on AMPK via the modulation of adiponectin levels has been shown
to inhibit PCa viability in prostate (PC-3) cancer cells [187], but, intriguingly, it increases
PCa cancer cell migration and the metastatic potential of human PCa cells [188]. In contrast
to the well-known metabolic benefits of AMPK upregulation, the role of ET in modulating
AMP activation in PCa remains elusive.
4. Future Directions
It would be interesting to conduct studies addressing the effects of ET alone, i.e.,
without any additional therapies [162]. It should be noted that a properly designed
randomized controlled trial with ET-only groups contrasted with ET plus additional
therapies will contribute significantly to improving the understanding of all interactions
between different therapeutical modalities.
The ET dosage (volume, intensity and frequency) and the perceived individual internal
load should be appropriately used but also reported and managed to understand the
influence of individual responses to ET and to close the gap in information related to the
prescription of effective ET programs.
Further research should address these issues to allow the guidelines for ET prescription
in patients with PCa to be updated. Currently, the American Cancer Society recommends a
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mixture of continuous aerobic exercise for 5 days per week or aerobic exercise 2–3 times
per week at a moderate intensity [189]. Although these guidelines were published in 2012,
they are still the most up-to-date version provided on their website [190]. The guidelines
for ET provided by the Prostate Cancer Foundation are more generic but are still based on
aerobic-based activities with an emphasis on vigorous intensity whenever possible [191].
Despite the acknowledged benefits of resistance exercise for PCa patients, there are neither
recommendations nor guidelines for practicing this modality [142]. Potentially, a greater
role should be granted to resistance exercise, in particular, to eccentric training. Moreover,
low versus high intensity exercise will likely promote differential benefits in PCa survivors,
and perhaps the two should be used complementarily [179].
The effects of ET on skeletal muscle and WAT have been studied extensively, but
the effects on the PPAT–tumor axis in PCa have not. Future studies should address this
question to understand how ET impacts this skeletal muscle–WAT–tumor axis.
5. Concluding Remarks
In summary, the ET program for PCa patients was demonstrated to promote several
positive adaptations in WAT by decreasing visceral adiposity and increasing skeletal mass
and strength, which may be reflected as positive modulation of the TME. While scarce,
the existing data seem to indicate that in cancer, particularly PCa, the skeletal muscle–
WAT–tumor axis may be affected by novel ET-induced adipokines/myokines secreted
by “trained” WAT and skeletal muscle (Figure 1); however, further research is needed.
Moreover, this skeletal muscle–WAT–tumor axis might be an essential mechanism by which
ET exerts its effects and investigation of this axis may improve the understanding of the
ET-related mechanisms underlying cancer.




Figure 1. Schematic view of hypothetical mechanisms underlying the effects of exercise training (ET) on the skeletal mus-
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tive modulation of the tumor microenvironment (TME). Furthermore, adipokine/myokine production and secretion in 
response to ET may modulate the skeletal muscle–WAT–tumor axis in cancer. However, the role of ET on PPAT and PCa 
tumor remains elusive, with conflicting data; BW, body weight; PPAT, periprostatic adipose tissue; PGC-1α, peroxisome 
proliferator-activated receptor gamma coactivator; AMPK, adenosine monophosphate-activated protein kinase; IL-6, in-
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